Journals / Molecular Imaging and Radionuclide Therapy / 2021 / Cilt: 30 - Sayı: 1

Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging

Pages
57–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

SAĞER, M. S., BİLGİÇ, S., BESLI, L. U., ASA, S., SAĞER, G., SONMEZOGLU, K. (2021). Active Giant Cell Vasculitis Diagnosis with 68Ga PSMA PET/CT Imaging. Molecular Imaging and Radionuclide Therapy, Cilt: 30 - Sayı: 1, 57–59. https://ajindex.com/articles/295017

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Chun AR, Jo HM, Lee SH, Chun HW, Park JM, Kim KJ, Jung CH, Mok JO, Kang SK, Kim CH, Kim BY. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. EndocrinolMetab (Seoul) 2015;30:71-77
  2. Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Curr Radiopharm 2018;11:4-13
  3. Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. 68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove “PS” From PSMA? Clin Nucl Med 2018;43:529-532
  4. Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol 2011;30: 1265-1275
  5. Balink H, Bennink RJ, van Eck-Smit BL, Verberne HJ. The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int 2014;2014:687608.